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replacement (TAVR) are unknown.
OBJECTIVES The aim of this study was to identify the incidence, predictors, and prognostic impact of major late
bleeding complications (MLBCs) ($30 days) after TAVR.
METHODS Clinical and echocardiographic outcomes of patients who underwent TAVR within the randomized cohorts
and continued access registries in the PARTNER (Placement of Aortic Transcatheter Valves) trial were analyzed after
stratifying by the occurrence of MLBCs. Predictors of MLBCs and their association with 30-day to 1-year mortality were
assessed.
RESULTS Among 2,401 patients who underwent TAVR and survived to 30 days, MLBCs occurred in 142 (5.9%) at a
median time of 132 days (interquartile range: 71 to 230 days) after the index procedure. Gastrointestinal complications
(n ¼ 58 [40.8%]), neurological complications (n ¼ 22 [15.5%]), and traumatic falls (n ¼ 11 [7.8%]) were identiﬁed as the
most frequent types of MLBCs. Independent predictors of MLBCs were the presence of low hemoglobin at baseline, atrial
ﬁbrillation or ﬂutter at baseline or 30 days, the presence of moderate or severe paravalvular leak at 30 days, and greater
left ventricular mass at 30 days. MLBCs were identiﬁed as a strong independent predictor of mortality between 30 days
and 1 year (adjusted hazard ratio: 3.91; 95% conﬁdence interval: 2.67 to 5.71; p < 0.001).
CONCLUSIONS MLBCs after TAVR were frequent and associated with increased mortality. Better individualized and
risk-adjusted antithrombotic therapy after TAVR is urgently needed in this high-risk population. (THE PARTNER TRIAL:
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2606P eriprocedural bleeding events aftertranscatheter aortic valve replace-ment (TAVR) are frequent and have
been shown to be associated with worse
prognosis (1–6). Although early bleeding
complications after TAVR are related mainly
to procedural or technical factors (e.g.,
vascular complications) (7–9), the cause, na-
ture, and impact of late bleeding (after 30
days) in this population remain unknown.
Given the advanced age and the presence of
multiple comorbidities, including atrialﬁbrillation (AF) or coronary artery disease, among
the currently treated TAVR population (10–20), it is
to be expected that late bleeding events, especially
in the context of routine dual-antiplatelet therapy
and/or anticoagulation, will be frequent and will
adversely affect long-term prognosis (21). As a ﬁrstSEE PAGE 2616step to better deﬁne and individualize antithrombotic
therapy after TAVR (3,21,22) and to inform future tri-
als for this population, we sought to characterize the
incidence, predictors, and impact of major late
bleeding complications (MLBCs; $30 days) on long-
term prognosis after TAVR using pooled data from
the multicenter, randomized PARTNER (Placement
of Aortic Transcatheter Valves)-1 trial, the random-
ized continued-access PARTNER trial, and the non-
randomized continued-access PARTNER registry.
METHODS
STUDY POPULATION. The PARTNER-1 trial was a
multicenter, randomized clinical trial comparing
TAVR with surgical aortic valve replacement for high-
risk patients (cohort A) and TAVR with medical ther-
apy for inoperable patients (cohort B) (14,15). After
completion of the randomized trial and before com-
mercial approval of the transcatheter heart valve
(SAPIEN, Edwards Lifesciences, Irvine, California),
additional patients were treated in a randomized
continued-access trial as well as in a nonrandomized
continued-access registry, with the same inclusion
and exclusion criteria as in the randomized trial. All
patients had severe native aortic stenosis docu-
mented on screening transthoracic echocardiography
within 30 days of enrollment and were evaluated bythe PARTNER Executive Committee. All other authors have repo
this paper to disclose. Sanjay Kaul, MD, MPH, served as Guest E
is manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
o listen to this issue’s audio summary by JACC Editor-in-Chief D
received May 13, 2014; revised manuscript received August 1, 202 surgeons for assessment of risk with surgical aortic
valve replacement. Important exclusion criteria in-
cluded bicuspid aortic valve disease, ejection fraction
<20%, renal failure, severe mitral regurgitation, se-
vere aortic regurgitation, recent gastrointestinal (GI)
bleeding, or a recent neurological event. Complete
inclusion and exclusion criteria have been presented
in the supplementary appendices to previous publi-
cations (14,15).
All patients undergoing TAVR received either a
23- or a 26-mm balloon-expandable transcatheter
heart valve delivered via either the transfemoral or
transapical approach on the basis of vascular access.
Annular assessments to determine valve size required
were site determined using transthoracic echo-
cardiography, transesophageal echocardiography, or
multislice computed tomography. All patients under-
went transthoracic echocardiography before discharge
and at clinical follow-up assessments, including
1 month, 6 months, and 1 year. The present analysis
included all patients who actually underwent TAVR
and survived up to 30 days. The institutional review
board at each participating site approved the study,
and all patients provided written informed consent.
STUDY ENDPOINTS. Bleeding complications were
deﬁned according to a modiﬁed version of the Valve
Academic Research Consortium criteria as described
in the PARTNER trial protocol and were restricted to
those events that occurred at or after 30 days
(14,15,23,24). Bleeding events were classiﬁed as either
major or minor. MLBCs were deﬁned as a clear site of
bleeding that met any 1 of the following criteria:
bleeding that caused death; bleeding that caused a
new hospitalization or prolonged hospitalization
$24 h because of treatment, bleeding that required
pericardiocentesis or an open and/or endovascular
procedure for repair or hemostasis, bleeding that
caused permanent disability (e.g., blindness, paraly-
sis, hearing loss), and bleeding that required trans-
fusion of >3 U of blood within a 24-h period. Minor
bleeding had to meet all of the following criteria:
a bleeding event that did not meet criteria for major
bleeding, clear site for bleeding, and loss of hemo-
globin >3 g/dl or loss of hematocrit >9%. Adjustment
for transfusions was included at 1 g/dl or 3% for
each unit of blood. Only major bleeding events are
reported in the present analysis.rted that they have no relationships relevant to the
ditor for this paper.
ntin Fuster.
r. Valentin Fuster.
14, accepted August 31, 2014.
TABLE 1 Types of Major Late Bleeding ($30 Days)
After TAVR (n ¼ 142)
Gastrointestinal 58 (40.8)
Neurological* 22 (15.5)
Trauma/fall* 11 (7.8)
Genitourinary 9 (6.3)
Chronic anemia 5 (3.5)
TAVR access-site related 3 (2.1)
Pulmonary 3 (2.1)
Other surgery† 3 (2.1)
Ears, nose, throat 2 (1.4)
Cardiac tamponade‡ 1 (0.7)
Unspeciﬁed 33 (23.2)
Values are n (%). In cases of multiple bleeding events between 30 and 365
days, only the ﬁrst bleeding event was counted. There were 11 patients of 142
with more than 1 late major bleeding event. *Includes 8 patients with initial falls
and subsequent neurological bleeding. †Hip surgery and knee surgery. ‡At
a subsequent percutaneous coronary intervention complicated by vessel
perforation.
TAVR ¼ transcatheter aortic valve replacement.
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2607The frequency of all-cause mortality, cardiovascu-
lar mortality, stroke, rehospitalization, and renal
failure requiring dialysis between 30 days and 1 year
of follow-up were reported, according to initial Valve
Academic Research Consortium deﬁnitions (23) or
according to a modiﬁed version of the Valve Academic
Research Consortium criteria as described in the
PARTNER trial protocol (14,15). An independent clin-
ical events committee adjudicated all adverse events.
Further extensive review of the source documents
was performed by one of the authors (P.G.) to better
characterize the causes of bleeding events. Indepen-
dent core laboratories analyzed all echocardiograms
and electrocardiograms. An independent academic
biostatistics group performed all data analyses.
STATISTICAL ANALYSIS. Continuous variables are
summarized as mean SD or as medians and quartiles,
as appropriate, and were compared using Student t
tests or Mann-Whitney rank sum tests accordingly.
Categorical variables were compared using chi-square
or Fisher exact tests. Survival curves for time-to-event
variables were constructed on the basis of all available
follow-up data using Kaplan-Meier estimates, and
comparisons were performed using the log-rank test.
Cox multivariate regression analysis (with a land-
mark analysis at 30 days for MLBCs) was performed to
identify independent predictors of MLBC (a ¼ 0.05).
The multivariate model was built by stepwise selec-
tion, with candidate variables being selected if they
were of clinical interest or satisﬁed the entry crite-
rion of p < 0.10 in the univariate analysis. To assess
the association between MLBCs and all-cause mor-
tality, Cox multivariate regression analysis (using
time-updated covariates for bleeding) was per-
formed, with variable selection performed as
described above. A 2-sided a level of 0.05 was used
for all statistical testing. All statistical analyses were
performed using SAS version 9.2 (SAS Institute Inc.,
Cary, North Carolina).
An additional analysis assessing the impact of the
presence of AF or atrial ﬂutter (either at baseline or at 30
days), as determined by an independent electrocardio-
graphic core laboratory, with the occurrence of MLBCs
was performed. Although the capture of oral anti-
coagulation at baseline or during the course of the study
was not required in the PARTNER trial, the presence of
AF, given the high comorbidity of the treated population
(>75 years of age, hypertension, valvular disease, prior
stroke), and the high likelihood of oral anticoagulation
use if AF was present among this high-risk population,
could be seen as a surrogate for oral anticoagulation use.
The present analysis was carried out by acade-
mic investigators at the Cardiovascular Research
Foundation.RESULTS
PATIENTS AND BASELINE CHARACTERISTICS. From
PARTNER trial cohort B (inoperable; n ¼ 164),
PARTNER trial cohort A (high risk but operable;
n ¼ 326), the randomized continued-access registry
(n ¼ 37), and the nonrandomized continued-access
registry (n ¼ 1,874), a total of 2,401 patients were
actually treated with TAVR, survived to 30 days,
and therefore were included in the present analysis.
The median follow-up of the entire studied popu-
lation was 1 year (365 days), with 2,323 patients
(96.8%) completing 1-year follow-up. MLBCs oc-
curred in 142 patients (5.9%) between 30 days
and 1 year. The median time of occurrence was
132 days (interquartile range: 71 to 230 days) after
the index procedure, with 91 (64.1%) occurring in-
side 6 months. The causes of major MLBCs are
summarized in Table 1. GI bleeding (n ¼ 58 [40.8%])
was the most frequent type of MLBC, with upper
GI bleeding being conﬁrmed in 22 patients (37.9%),
lower GI bleeding in 13 patients (22.4%), and GI
bleeding of undetermined origin in 23 patients
(39.7%). Neurological bleeding occurred in 22 pa-
tients (15.5%). Importantly, mechanical falls or trauma
was identiﬁed in 8 of these patients (36.4%), subse-
quently leading to traumatic intracranial bleeding.
Baseline, echocardiographic, and procedural char-
acteristics of patients stratiﬁed according to the
occurrence of MLBC are shown in Tables 2 and 3. Pa-
tients with MLBCs were more frequently male and
hypertensive, had more baseline AF, and had lower
baseline hemoglobin and white blood cell counts.
TABLE 2 Baseline Characteristics According to Occurrence of
Major Late Bleeding
Late Bleeding
(n ¼ 142)
No Late Bleeding
(n ¼ 2,259) p Value
Age, yrs 84.32  6.49 84.43  7.23 0.84
Men 89/142 (62.7) 1,171/2,259 (51.8) 0.01
BMI, kg/m2 26.02  5.24 26.87  6.31 0.07
Diabetes 58/141 (41.1) 832/2,258 (36.8) 0.31
Hyperlipidemia 124/141 (87.9) 1,886/2,258 (83.5) 0.17
Smoking 64/141 (45.4) 1,098/2,258 (48.6) 0.46
Hypertension 136/141 (96.5) 2,071/2,257 (91.8) 0.05
Angina 34/141 (24.1) 483/2,258 (21.4) 0.45
Stable 29/31 (93.5) 400/436 (91.7) 1.00
Unstable 2/31 (6.5) 36/436 (8.3) 1.00
CHF, NYHA class III or IV 134/142 (94.4) 2143/2259 (94.9) 0.79
Coronary artery disease 110/141 (78.0) 1,755/2,257 (77.8) 0.94
Prior myocardial infarction 35/139 (25.2) 583/2,248 (25.9) 0.84
Prior PCI 62/140 (44.3) 883/2,255 (39.2) 0.23
Prior CABG 66/141 (46.8) 960/2,257 (42.5) 0.32
Prior stroke or TIA 44/139 (31.7) 568/2,213 (25.7) 0.12
Carotid disease 33/137 (24.1) 578/2,191 (26.4) 0.55
Peripheral vascular disease 60/139 (43.2) 948/2,234 (42.4) 0.87
Porcelain aorta 4/142 (2.8) 88/2,257 (3.9) 0.51
Pulmonary hypertension 50/136 (36.8) 844/2,157 (39.1) 0.58
Frailty 15/136 (11.0) 279/2,156 (12.9) 0.52
Permanent pacemaker 39/141 (27.7) 473/2,257 (21.0) 0.06
AF 45/141 (31.9) 467/2,233 (20.9) 0.002
Atrial ﬂutter 3/141 (2.1) 42/2,234 (1.9) 0.75
Renal disease,
creatinine $2 mg/dl
21/141 (14.9) 372/2,256 (16.5) 0.62
Liver disease 7/141 (5.0) 54/2,255 (2.4) 0.09
COPD 67/142 (47.2) 997/2,259 (44.1) 0.48
Hemoglobin, g/dl 11.53  1.41 11.78  1.85 0.04
WBC, 1,000 cells/ml 6.62  1.85 7.58  16.60 0.01
Platelets, cells/mm3 186, 143–245 197 (156–246) 0.92
Creatinine clearance, ml/min 45.20  20.49 45.41  22.29 0.92
Albumin, g/dl 3.69  0.47 4.39  9.06 0.005
STS score 11.69  3.94 11.37  4.04 0.35
Logistic EuroSCORE 25.78  15.39 26.43  16.33 0.65
Values are mean  SD, n/N (%), or median (interquartile range).
AF ¼ atrial ﬁbrillation; BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting; CHF ¼
congestive heart failure; COPD¼ chronic obstructive pulmonary disease; EuroSCORE ¼ European
System for Cardiac Operative Risk Evaluation; NYHA ¼ New York Heart Association; PCI ¼
percutaneous coronary intervention; STS ¼ Society of Thoracic Surgeons; TIA ¼ transient ischemic
attack; WBC ¼ white blood cell.
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2608During the procedure, these patients most likely
required larger valves (26 mm) and had a lower rate of
successful procedures, with more frequent valve
embolization.
Within 30 days, there was no difference in the rates
of stroke or vascular complications, but patients with
MLBCs had a slightly higher rate of major bleeding
and AF than those without MLBCs. Both groups had
similar lengths of hospital stay.
Echocardiographic ﬁndings at baseline and 30 days
are shown in Table 3. The rate of moderate or severeaortic regurgitation (total and paravalvular leak
[PVL]) was signiﬁcantly higher among patients with
subsequent MLBCs. Also, moderate or severe mitral
regurgitation, left ventricular mass, and diastolic and
stroke volumes were more elevated among patients
with MLBCs.
No major differences were seen in antiplatelet
therapy (aspirin and/or clopidogrel) regimens be-
tween the 2 groups at 30-day and 6-month follow-up
(Online Appendix).
PREDICTORS OF MLBCS. Variables associated with
MLBCs are summarized in Table 4. After multivariate
analysis, moderate or severe aortic PVL (at 30 days),
AF or atrial ﬂutter at baseline or 30 days, greater left
ventricular mass, and low baseline hemoglobin were
identiﬁed as independent predictors of MLBCs after
TAVR.
CLINICAL OUTCOMES. Between 30 days and 1 year,
the occurrence of MLBC was associated with signiﬁ-
cantly higher rates of death, cardiac death, major
stroke, and rehospitalization (Figures 1A to 1D), with a
consistent impact among major patient subgroups
(Figure 2). MLBCs also were associated with an
increased risk for renal failure needing dialysis (3.9%
vs. 1.5%; p ¼ 0.02). After multivariate analysis
adjusting for clinical, echocardiographic, and proce-
dural characteristics, as well as outcomes, the occur-
rence of MLBCs was identiﬁed as a strong predictor
of mortality between 30 days and 1 year (adjusted
hazard ratio: 3.83; 95% conﬁdence interval: 2.62 to
5.61; p < 0.001) (Table 5).
IMPACT OF AF OR ATRIAL FLUTTER. Among patients
with AF, 8.6% (58 of 671) had MLBCs, compared with
4.8% (84 of 1,730) of those with no AF. No interaction
was demonstrated between the presence of AF and
MLBCs with regard to the occurrence of mortality
(p for interaction ¼ 0.83). The presence of AF, espe-
cially when MLBCs occurred, was associated with a
poor prognosis and high rate of mortality (Central
Illustration, Online Appendix).
DISCUSSION
This study is the ﬁrst to speciﬁcally evaluate and
assess the incidence, predictors, and impact of
MLBCs on long-term prognosis after TAVR. The main
results of the present study are as follows: 1) among
patients treated with TAVR, MLBCs ($30 days) were
relatively frequent, occurring in approximately 6%
of patients; 2) GI and neurological origin were the
most frequent identiﬁable sites of bleeding; 3) inde-
pendent predictors of MLBCs after TAVR included
the presence of AF, residual moderate or severe
TABLE 3 Procedural and Echocardiographic Characteristics
According to the Occurrence of Major Late Bleeding
Late
Bleeding
(n ¼ 142)
No Late
Bleeding
(n ¼ 2,259) p Value
Procedural
characteristics
Approach
Transfemoral 87/142 (61.3) 1,324/2,259 (58.6) 0.53
Transapical 55/142 (38.7) 935/2,259 (41.4) 0.53
Valve size
23-mm 62/141 (44.0) 1,156/2,215 (52.2) 0.058
26-mm 79/141 (56.0) 1,058/2,215 (47.8) 0.057
Successful valve
implantation
136/140 (97.1) 2,197/2,247 (97.8) 0.56
Migration or
embolization
4/56 (7.1) 11/839 (1.3) 0.01
Artery closure
Surgical cutdown 47/140 (33.6) 784/2,252 (34.8) 0.76
Closure device 38/140 (27.1) 546/2,252 (24.2) 0.44
Device success 113/142 (79.6) 1,928/2,258 (85.4) 0.06
Procedure success 106/142 (74.6) 1,858/2,258 (82.3) 0.02
Post-procedure
Aortic valve area,
cm
2.13  0.93 2.19  2.79 0.69
Mean AV gradient,
mm Hg
6.40  5.31 7.31  8.67 0.16
Peak AV gradient,
mm Hg
6.11  6.27 8.12  12.14 0.02
Vascular
complications,
<30 days
19 (13.4) 273 (12.1) 0.64
Major 10 (7.0) 141 (6.2) 0.70
Bleeding, <30 days 19 (13.4) 208 (9.2) 0.11
Major 19 (13.4) 158 (7.0) 0.005
Stroke or TIA,
<30 days
8 (5.6) 76 (3.4) 0.16
Major 5 (3.5) 48 (2.1) 0.28
Minor 2 (1.4) 18 (0.8) 0.44
TIA 1 (0.7) 10 (0.4) 0.65
AF, at 30 days 46/129 (35.7) 446/2,074 (21.5) 0.0002
Atrial ﬂutter,
at 30 days
3/129 (2.3) 40/2,074 (1.9) 0.74
Days in hospital,
post-procedure
6.29  3.18 6.26  2.68 0.93
Continued in the next column
TABLE 3 Continued
Late
Bleeding
(n ¼ 142)
No Late
Bleeding
(n ¼ 2,259) p Value
Echocardiographic
characteristics
Baseline
AV peak gradient,
mm Hg
67.30  21.12 71.78  22.29 0.02
AV mean gradient,
mm Hg
41.08  13.53 44.41  14.25 0.008
AV area (EOA),
cm2
0.67  0.20 0.65  0.19 0.11
AV annular
diameter, cm
1.97  0.28 1.90  0.27 0.01
Total aortic
regurgitation
moderate or
severe
18/140 (12.9) 234/2,207 (10.6) 0.40
Mitral regurgitation
moderate or
severe
40/138 (29.0) 475/2,204 (21.6) 0.04
LVEDV, ml 149.31  54.21 132.70  49.68 0.007
LVESV, ml 75.93  43.47 67.09  41.19 0.08
LV ejection
fraction, %
52.62  12.78 52.46  12.92 0.89
Stroke volume, ml 73.25  23.08 65.62  20.62 0.003
LV mass, g 266.40  75.48 249.03  76.25 0.01
30 days
AV peak gradient,
mm Hg
17.18  6.78 17.78  7.77 0.35
AV mean gradient,
mm Hg
8.94  3.81 9.33  4.29 0.27
AV area (EOA),
cm2
1.77  0.48 1.70  0.49 0.16
Total AR moderate
or severe
29/124 (23.4) 244/2,083 (11.7) 0.0001
Paravalvular AR
moderate or
severe
26/123 (21.1) 204/2,072 (9.8) <0.0001
Mitral regurgitation
moderate to
severe
32/124 (25.8) 366/2,077 (17.6) 0.02
LVEDV, ml 149.70  54.56 134.24  49.34 0.04
LVESV, ml 72.26  45.30 64.28  37.26 0.25
LV ejection
fraction, %
54.54  10.72 54.20  11.17 0.74
Stroke volume, ml 77.22  20.35 69.92  22.08 0.03
LV mass, g 259.64  77.66 232.44  73.89 0.0001
Values are n/N (%) or mean  SD.
AR ¼ aortic regurgitation; AV ¼ aortoventricular; EOA ¼ effective oriﬁce area;
LV ¼ left ventricular; LVEDV ¼ left ventricular end-diastolic volume; LVESV ¼ left
ventricular end-systolic volume; TIA ¼ transient ischemic attack.
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2609PVL, baseline hemoglobin, and increased left ven-
tricular mass; and 4) MLBCs were associated with
an increased rate of mortality and morbidity between
30 days and 1 year.
To the best of our knowledge, the present study
is the ﬁrst to speciﬁcally examine bleeding events
after TAVR beyond the periprocedural period ($30
days) and to demonstrate their strong association
with increased mortality. Indeed, MLBCs were
associated with a 4-fold increase in late mortality
among the TAVR population enrolled in the PART-
NER trial. Several groups have previously described
the negative impact of periprocedural bleedingand red blood cell transfusions after TAVR pro-
cedures (2,4–6,8). The present study reinforces
and extends beyond the periprocedural period the
detrimental effect of major bleeding events and
identiﬁes a potential area for improved patient
care. Although much attention initially focused on
the improvement of acute outcomes (advances in
device technologies, optimization of implantation
TABLE 4 Multivariate Predictors of Major Late Bleeding
HR (95% CI) p Value
Moderate to severe PVL* 2.14 (1.26–3.63) 0.005
AF/atrial ﬂutter† 1.87 (1.28–2.73) 0.001
LV mass (per 10-g increase)* 1.04 (1.01–1.06) 0.002
Baseline hemoglobin (g/dl) 0.85 (0.75–0.95) 0.006
Candidate variables for the model were age, sex, AF or atrial ﬂutter at baseline or
at 30 days, procedural success, moderate or severe PVL at 30 days, renal insuf-
ﬁciency at baseline (creatinine >2 mg/dl), body mass index, Society of Thoracic
Surgeons score, hypertension, baseline hemoglobin, LV end-diastolic dimension at
30 days, aortoventricular annulus at baseline, LV mass at 30 days, and moderate
to severe mitral regurgitation at 30 days. *At 30 days. †At baseline or 30 days.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; PVL ¼ paravalvular leak; other
abbreviations as in Tables 2 and 3.
FIGURE 1 Kaplan-Meier Curves Showing Cumulative Adverse Event Rates Through 1 Year Be
No Late Bleeding Complications
Late Major Bleeding No Late M
50
40
30
20
10
0
40
30
20
10
0
30 60 90 120 150 180 210 240 270 300 330 360
30 60 90 120 150 180 210 240 270 300 330 360
De
at
h 
(%
)
Re
pe
at
 H
os
pi
ta
liz
at
io
n 
(%
)
Time in Days
Time in Days
34.0%
16.5%
28.3%
14.4%
HR: 2.25 [95% CI: 1.67, 3.04]
P < 0.001
HR: 2.13 [95% CI: 1.50, 3.03]
P < 0.001
Number at risk:
Late Major Bleeding
No Late Major Bleeding
142
2259 2128 1995
130 110 101
1894 1673
86
Number at risk:
Late Major Ble
No Late Major 
Number at risk:
Late Major Ble
No Late Major 
Number at risk:
Late Major Bleeding
No Late Major Bleeding
142
2259 2026 1838
119 91 78
1727 1494
62
A B
C D
Comparison of cumulative adverse event rates through 1 year in patients with late bleeding comp
(B) cardiac mortality, (C) rehospitalization, and (D) major stroke. CI ¼ conﬁdence interval; HR ¼
Généreux et al. J A C C V O L . 6 4 , N O . 2 4 , 2 0 1 4
Late Bleeding After TAVR D E C E M B E R 2 3 , 2 0 1 4 : 2 6 0 5 – 1 5
2610techniques, and enhanced operator experience),
leading to a dramatic reduction in periprocedural
complications (25–27), this study demonstrates
that reducing later adverse events (such as MLBCs)
is also crucial if long-term prognosis is to be
improved. Fortunately, prospective studies are on-
going (Aspirin Versus Aspirin þ Clopidogrel Fol-
lowing Transcatheter Aortic Valve Implantation
[NCT01559298]) and are expected to provide some
answers to this important question.
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2611appear to be related mainly to patients’ bleeding
susceptibility, which is often “triggered” by the
antithrombotic agent used. Unsurprisingly, GI
bleeding was the most frequently identiﬁable source
of major bleeding after 30 days. Bleeding from
arteriovenous malformation distributed throughout
the GI tract is a well-described syndrome (Heyde’s
syndrome) associated with severe aortic stenosis,
accounting for a signiﬁcant proportion of GI bleeding
in this population (28,29). Similarly, benign and
malignant tumors are frequent in this group of pa-
tients. Appropriate screening, such as gastroscopy,
colonoscopy (either before or soon after the TAVR
procedure), and the use of gastroprotection (i.e.,
proton pump inhibition), could be considered during
the high-risk period and may help prevent a pro-
portion of these GI bleeds. Further studies are
needed to evaluate the risk and beneﬁts of these
strategies.
The association between MLBCs and moderate or
severe PVL is previously unrecognized and mayrepresent a mechanism underlying the excess mor-
tality and morbidity associated with residual moder-
ate or severe PVL among patients surviving beyond
30 days post-TAVR. Indeed, several groups have
previously noted that high shear stress and ﬂow -
turbulence may lead to the loss (cleavage) of essential
proaggregation proteins (high–molecular weight von
Willebrand factor), leading to an increased suscepti-
bility to bleeding (acquired von Willebrand disease
type 2A) (28–31). This hematologic disturbance has
been shown to rapidly resolve with treatment of the
aortic stenosis or any anatomic situation causing
high-ﬂow turbulence (28–32). Our ﬁndings, in which
patients with underlying high-risk bleeding proﬁles,
combined with highly turbulent ﬂow through
“crushed” heavily calciﬁed native valve leaﬂets and
underexpanded leaking prostheses, suggest that
post-TAVR paravalvular aortic regurgitation may
represent the perfect storm for acquired throm-
bophilia, ultimately leading to major bleeding
events. This biological phenomenon may be ampliﬁed
TABLE 5 Independent Predictors of 30-Day to 1-Year Mortality
Predictor Adjusted HR (95% CI) p Value
Major stroke within 1 yr 5.44 (3.33–8.90) <0.0001
Major late bleeding* 3.83 (2.62–5.61) <0.0001
AF/atrial ﬂutter† 2.03 (1.60–2.58) <0.0001
Moderate to severe PVL† 1.70 (1.27–2.27) 0.0004
Hemodynamic support use
(CPB or IABP)
1.63 (1.10–2.39) 0.01
Renal insufﬁciency
(creatinine $2 mg/dl)
1.61 (1.23–2.10) 0.0006
Severe pulmonary hypertension 1.40 (1.11–1.77) 0.005
Liver disease 1.78 (1.00–3.19) 0.051
Moderate to severe MR† 1.30 (1.00–1.70) 0.051
Platelet count at baseline 1.00 (1.00–1.00) 0.02
AV mean gradient at baseline 0.99 (0.98–0.99) 0.002
Dual-antiplatelet therapy† 0.76 (0.60–0.98) 0.03
Candidate variables for the model were male sex, bleeding <30 days, BMI,
Society of Thoracic Surgeons score, pulmonary hypertension, renal insufﬁ-
ciency (creatinine $2 mg/dl), liver disease, chronic obstructive pulmonary
disease (oxygen dependent), migration or valve embolization, hemodynamic
support use (CPB or IABP), albumin at baseline, platelet count at baseline,
hemoglobin at baseline, dual-antiplatelet therapy at 30 days, baseline
left ventricular ejection fraction, AV mean gradient at baseline, moderate
to severe PVL at 30 days, moderate to severe MR at 30 days, AF at baseline
or 30 days, and unplanned arterial vascular procedure. One-year major
stroke was the time-dependent covariable. *Between 30 days and 1 year.
†At 30 days.
CPB ¼ cardiopulmonary bypass; IABP ¼ intra-aortic balloon pulsation;
MR ¼ mitral regurgitation; other abbreviations as in Tables 2 and 4.
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2612by using aggressive antiplatelet therapy and/or anti-
coagulation therapy (21). This ﬁnding reinforces the
importance of optimizing valve implantation to
minimize the presence of signiﬁcant residual PVL
(33–37), not only to avoid its detrimental hemody-
namic effect on the left ventricle but also to restore a
normal “biological-hematological” homeostasis and
decrease the risk for subsequent major bleeding
events. The association of increased left ventricular
mass with future MLBCs is intriguing and inter-
esting. Although this association is most likely
multifactorial, the hypothesis of increased ﬂow tur-
bulence leading to increased bleeding tendency
may also be an explanation. That said, given the
retrospective nature of our analysis and the presence
of potential residual confounders despite a well-
conducted multivariate analysis, this ﬁnding can
only be identiﬁed as hypothesis generating at this
point.
Patients with AF, at either baseline or post-
procedurally, have been shown to represent a high-
risk population with worse outcomes and increased
mortality after TAVR (38–41). Our report reinforces
these previous results, showing that patients with
AF have a higher rate of death, because of a higher
occurrence of MLBCs or thromboembolic events.
Further studies may help determine the beststrategies to manage AF among this group of high-risk
patients.
STUDY STRENGTHS AND LIMITATIONS. This study
has some important strengths. It is the largest study
to use both an independent echocardiographic core
laboratory and an independent clinical events com-
mittee, providing extensive analysis and allowing the
identiﬁcation of a meaningful association between
speciﬁc echocardiographic parameters (e.g., PVL) and
important clinical ﬁndings (e.g., bleeding). Nonethe-
less, several important limitations of the present
analysis should be acknowledged. First and foremost,
systematic capture of anticoagulation regimens
(e.g., with warfarin) was not performed during the
different PARTNER studies. Although we acknowl-
edge the central importance of such information
when appraising causes and correlates of major
bleeding events, our report still brings meaningful
insight regarding the incidence and impact of MLBCs
after TAVR and raises awareness of the importance
and urgency to better deﬁne the safest and most
effective post-procedural antithrombotic therapy,
particularly among patients with AF. That said, given
the high thromboembolic risk proﬁle of this popula-
tion, most of the TAVR patients diagnosed with AF
were on, or should have received, anticoagulation
therapy. It is likely that the strong association be-
tween AF and bleeding, as well as AF and mortality,
in the TAVR population represents the effect of oral
anticoagulation either alone or in combination with
antiplatelet therapy in such patients. This ﬁnding
clearly illustrates the extreme challenge of treated AF
in the TAVR population and the need to better deﬁne
the optimal antithrombotic regimens in such patients.
Second, patients with recent GI bleeding or
neurological events (ischemic or hemorrhagic) were
excluded from the PARTNER trial. The inclusion
of such patients (as in real-world practice) would
have likely resulted in an even higher rate of
MLBCs.
Third, the deﬁnition of major bleeding used in the
present report lies at the extreme range of bleeding
severity, particularly in the outpatient setting. It is
possible that a more reﬁned, detailed bleeding clas-
siﬁcation, such as that proposed by the Bleeding
Academic Research Consortium (BARC), could have
been used and may have led to different ﬁndings (42).
The bleeding deﬁnitions used in the present report
correspond approximately to BARC classes 3 and 5,
depending on the severity (leading to death or not).
However, BARC classiﬁcation has not been validated
in the TAVR space, and data collection unfortunately
does not allow BARC bleeding readjudication. Finally,
CENTRAL ILLUSTRATION Kaplan-Meier Curves Showing Cumulative Death Rates Through 1 Year, According
to Bleeding and AF Status
Time (days)
60
70
30
10
20
40
50
0
30 60 12090 150 180 240210 270 300 330 360
58
613
84
1,646
52
551
78
1,577
38
498
72
1,497
34
459
67
1,435
26
394
60
1,279
48.7%
26.2%
23.9%
12.9%
De
at
h 
(%
)
Number at Risk:
AF and MLB
AF and No MLB
No AF and MLB
No AF and No MLB
AF and Major Late Bleeding
AF and No Major Late Bleeding
No AF and Major Late Bleeding
No AF and No Major Late Bleeding
Log-Rank P-Value <0.0001
Généreux, P. et al. J Am Coll Cardiol. 2014; 64(24):2605–15.
The presence of atrial ﬁbrillation (AF) or atrial ﬂutter and bleeding was associated with a signiﬁcant increase in mortality rates between
30 days and 1 year compared with patients with no AF and/or no late bleeding (LB) events. MLB ¼ major late bleeding.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Among high-risk
or inoperable patients undergoing TAVR, those who develop
major bleeding complications more than 30 days after the pro-
cedure exhibit more than twice the mortality rate of those
without late post-procedural bleeding.
TRANSLATIONAL OUTLOOK: Future studies are needed to
deﬁne predictors of late bleeding complications and tailored
antithrombotic therapy strategies for patients undergoing TAVR.
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2613although we adjusted for imbalances in a number
of important covariates, potential unmeasured con-
founders may still be present. The results of this
observational post hoc analysis should therefore be
considered hypothesis generating.
CONCLUSIONS
MLBCs (between 30 days and 1 year) after TAVR
were frequent and associated with increased mor-
tality. The observed association between moderate
or severe PVL and the occurrence of MLBCs is
interesting and deserves further investigation. Bet-
ter individualized and risk adjusted antithrombotic
therapy after TAVR is urgently needed in this high-
risk population.
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